Daré Bioscience (DARE) investor relations material

Strategy and market opportunity

• Focus on evidence-based, fit-for-purpose solutions for unmet needs across contraception, menopause, sexual health, fertility and other areas; direct commercialization is a priority for 2026-27.

• Portfolio strategy targets therapeutic gaps where proof-of-concept science exists, including products adapted from FDA-approved drugs or dosage forms.

• Women’s health markets are large and form factor matters; management cited more than $75 million in non-dilutive funding secured to advance the portfolio.

Commercial products and launch plans

• Flora Sync vaginal probiotic launched in summer 2026; a 3-day course restored the microbiome in 96% of trial participants, with 90% maintaining it at 2 weeks; sold online and through clinics.

• DARE to PLAY sildenafil cream showed increased blood flow within 10-15 minutes and improved physical arousal sensations; 503B dispensing is expected later in 2026, while FDA approval work continues.

• The integrated DARE Health Hub supports online orders and telehealth prescriptions; clinician education, sampling and social media are central to customer outreach.

• Management described 503B as large-scale GMP compounding at FDA-inspected outsourcing facilities, offering a route to meet demand while pursuing a longer-term FDA registration pathway.

Development pipeline and catalysts

• Ovaprene, a once-monthly hormone-free contraceptive, is in its phase III registration trial; enrollment is expected to finish in 2026 and data are expected in 2027. Phase II projected 86%-91% typical-use effectiveness.

• DARE-HPV, an investigational vaginal antiviral combination, is in an ARPA-H-funded phase II trial, with data expected in 2027.

• DARE-HRT1 menopause ring could reach market in 2027; existing phase I/II data showed estradiol at premenopausal levels and protective progesterone levels with a once-monthly product.

• A non-hormonal vaginal treatment for sexual pain is cleared for phase II; a progesterone ring for IVF and preterm birth is planned for an NIH-funded phase I study.

• DARE-LARC1 programmable implant has drawn interest for potential use in metabolic disorders and obesity; the program is grant-funded.